The Pathology and Tissue Informatics Core (PTIC) is essential for the success of the Vanderbilt Breast Cancer SPORE. The goal of the PTIC is to facilitate the clinical and translational research aims of this renewal application via three primary missions: 1) To provide human tissue and body fluid collection, processing and quality control according to standardized protocols by trained personnel; 2) To provide specialized technical and diagnostic histo-pathology services in human and mouse tumors including expertise in performance and interpretation of immunohistochemistry (IHC), immunofluorescence (IF), and fluorescence in situ hybridization (FISH) assays, diagnostic and cellularity assessments on all procured tissue used for correlative studies, and construction of tissue microarrays; and 3) To provide high-quality and efficient informatics support for collection, pathological and clinical annotation, tracking and distribution of breast tissues for translational research. The core is co-directed by an expert breast pathologist and the Vanderbilt Ingram Cancer Center (VICC) Director of Clinical Informatics who oversees the development and maintenance of the clinical research information systems. All tissue is collected from patients with breast cancer consented for enrollment into SPORE and VICC protocols or under the auspices of the Vanderbilt Breast Tissue and Body Fluids Repository. The Repository, established in the initial funding period of this Breast SPORE, is now a robust collection of over 25,000 tissue, blood and urine samples, available to Breast SPORE investigators, which are linked to clinical data through the Breast SPORE Database. The core provides best practices oversight of optimal tissue utilization for each tissue specimen enabling numerous correlative studies such as gene arrays, sequencing and IHC to be performed on small tumor samples. The core will be directly involved in the analysis of these studies and will interact extensively with all the projects. The PTIC provides a centralized mechanism for performance of specialized technical and diagnostic histo- pathology services, critical to the success of the Breast SPORE, preventing the inefficiencies of tissue acquisition by individual projects and the performance of tissue-based assays by inexperienced hands.
The complexity of the tissue procurement process, critical nature of the sample quality assurance, intensive oversight required for optimal tissue utilization, high quality specialized technical and diagnostic histo- pathology services and the necessary informatics to efficiently support the missions of the Vanderbilt Breast Cancer SPORE justifies the need of a Pathology and Tissue Informatics core.
|Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249|
|Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435|
|Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017|
|Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21|
|Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194|
|Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248|
|Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :|
|Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858|
|Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191|
|Jovanovi?, Bojana; Sheng, Quanhu; Seitz, Robert S et al. (2017) Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer 17:241|
Showing the most recent 10 out of 341 publications